Where does Ryzera Corp. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Ryzera Corp. ranks #42,753 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Ryzera Corp. hold?

Ryzera Corp. holds 6 US utility patents granted between 2019 and 2025, spanning 1 technology areas.

What is Ryzera Corp.'s Innovation Score?

Ryzera Corp. has an Innovation Score of 12.8 out of 100 (2nd percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Ryzera Corp.'s patent grant rate increasing or decreasing?

Ryzera Corp.'s recent grant velocity is +300% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Ryzera Corp.'s patents?

Ryzera Corp.'s patents average 4.2 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Ryzera Corp. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Ryzera Corp.

Q: What technology areas does Ryzera Corp. focus on?

Ryzera Corp.'s top technology area is A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs) with 1 patents, ranking #2,337 of 3,082 assignees active in that subclass. Grants appear in 1 CPC subclasses total.

USPTO PatentsView assignee record - 6 granted patents across 1 technology areas, recorded in grant years 2019–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Ryzera ranks #42,753 of 49,997 tracked US assignees by granted-patent volume, with 6 patents across 1 technology areas.

#42,753
of 49,997 US assignees by volume: 2nd percentile
by Innovation Score (12.8/100): 4.2
avg claims per patent: +300%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R42753 · US Corporation #42,753 · 6 grants

GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-LOW · CLAIMS-SPARSE · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 6 grants
LOWER-Q #42,753/49,997
PHOTO-FINISH Röchling Automotive SE
CPC-NARROW A61F · 1 areas
INNOV-LOW 12.8/100
CLAIMS-SPARSE 4.2 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +300% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Röchling Automotive SE (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Ryzera’s 12.8 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 6.7 pts (53%) Velocity 0.0 pts (0%) Breadth 3.5 pts (28%) Claim depth 2.5 pts (20%)

Qualcomm Incorporated · highest

85
Ryzera · this assignee

13
3D Lighting… · lowest

7

What this shows Ryzera's Innovation Score is 12.8/100 (2nd percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Ryzera?

Each dot is one of Ryzera’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Ryzera’s own 4.2 claims/patent is at or below the 14.3 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Ryzera vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Ryzera's grants concentrate

Ryzera Corp. is a focused PatentsView assignee: 1 CPC subclasses with 16.7% of grants classified under A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device). Peak complete grant year is 2020 (4 grants) versus a trough of 1 in 2019. By volume, Ryzera sits between Rules Based Medicine Inc. and S H Kelkar & Company Limited.

Rules Based Medic…

6
Rupp Marine

6
Ruumi Cup

6
Rymed

6
Röchling Automoti…

6
S & M Precast

6
S & S Numerical C…

6
S H Kelkar &

6
Ryzera ◀

6

What this shows Ryzera holds 6 patents at rank #42,723, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Ryzera

By rank, the assignees closest to #42,723 in granted patent volume.

Leaders in A61F (Filters Implantable Into Blood Vessels)

Other assignees with the most granted patents in Ryzera's primary technology class.

Ryzera's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

13 2nd percentile higher than 2% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2019–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.

View data table

Ryzera Corp. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2019	1	16.7%
2020	4	66.7%
2025partial year	1	16.7%

Which technologies does Ryzera Corp. patent most?

A61F - Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs 1

Top 1 of 1 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Ryzera Corp.'s patent record in context - here's where to go next.

Ryzera Corp.'s lead technology class is A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device), 16.7% of its portfolio - see every assignee active in that class. Explore A61F
Ranked #42,753 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Ryzera Corp. against Rules Based Medicine Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 12.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.